<p>根据公司在最近向美国证券交易委员会（SEC）提交的文件，Wellington Shields Capital Management LLC 在第三季度收购了 Insmed, Inc.（NASDAQ:INSM - 免费报告）的新股份。该基金收购了 8,472 股这家生物制药公司的股票，价值约为 1,220,000 美元。</p>
<ul>
<li>罗素再平衡：3 只准备上涨的股票</li>
</ul>
<p>其他几家机构投资者和对冲基金也买卖了该股票的股份。Wellington Shields &amp; Co. LLC 在第三季度收购了价值 569,000 美元的 Insmed 新股份。Bessemer Group Inc.在第三季度将其在 Insmed 的股份增加了 137.5%。Bessemer Group Inc.现在拥有 836 股这家生物制药公司的股票，价值 121,000 美元，此前在此期间又购买了 484 股。SBI Securities Co. Ltd.在第三季度将其在 Insmed 的持仓增加了 404.9%。SBI Securities Co. Ltd.现在拥有 207 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。Savant Capital LLC 在第三季度将其在 Insmed 的持仓增加了 36.7%。Savant Capital LLC 现在拥有 2,783 股这家生物制药公司的股票，价值 401,000 美元，此前在上个季度又购买了 747 股。最后，Bridges Investment Management Inc.在第三季度购买了价值约 221,000 美元的 Insmed 新股份。</p>
<h2>分析师设定新目标价</h2>
<p>INSM 最近成为几份研究报告的主题。巴克莱在 1 月 27 日的报告中开始覆盖 Insmed。他们为该公司设定了 “增持” 评级和 231.00 美元的目标价。HC Wainwright 在 12 月 18 日的研究报告中将 Insmed 的目标价从 240.00 美元下调至 230.00 美元，并为该公司设定了 “买入” 评级。瑞银集团在 1 月 6 日的研究报告中将 Insmed 的目标价从 223.00 美元下调至 215.00 美元，并对该股票设定了 “买入” 评级。富国银行在 12 月 18 日的研究报告中为 Insmed 设定了 195.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 16 日的报告中将 Insmed 的目标价从 216.00 美元上调至 230.00 美元，并给予该股票 “增持” 评级。三位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 203.45 美元。</p>
<ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
<p><strong>阅读我们关于 INSM 的最新股票报告</strong></p>
<h2>Insmed 股票表现</h2>
<p>NASDAQ INSM 在周五开盘价为 149.86 美元。该公司的 50 日移动平均价格为 174.90 美元，200 日移动平均价格为 159.93 美元。该公司的市值为 319.6 亿美元，市盈率为-24.21，贝塔值为 1.11。该公司的债务与股本比率为 0.59，流动比率为 4.63，速动比率为 4.34。Insmed, Inc.的 1 年最低价为 60.40 美元，1 年最高价为 212.75 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，内部人士 Michael Alexander Smith 在 2 月 3 日的交易中出售了 640 股该公司的股票。该股票以平均价格 156.27 美元出售，总交易额为 100,012.80 美元。出售完成后，该内部人士直接持有 56,397 股公司的股票，价值为 8,813,159.19 美元。这笔交易代表其持仓减少了 1.12%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站获取。此外，首席财务官 Sara Bonstein 在 2 月 3 日的交易中出售了 748 股 Insmed 股票。该股票以平均价格 156.34 美元出售，总价值为 116,942.32 美元。出售后，首席财务官在公司中持有 79,758 股，价值为 12,469,365.72 美元。这笔交易使其持股减少了 0.93%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了 274,857 股公司股票，价值为 50,121,247 美元。内部人士持有公司股票的 3.00%。</p>
<h2>Insmed 公司简介</h2>
<p>（免费报告）</p>
<p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，专注于靶向药物递送技术和新型制剂的研发，旨在改善治疗选择有限的患者的临床结果。</p>
<p>该公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比 Insmed 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><strong>想看看其他对冲基金持有的 INSM 吗？</strong> 请访问 HoldingsChannel.com，获取 Insmed, Inc.（NASDAQ:INSM - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

<p>威灵顿希尔兹资本管理公司在第三季度投资了 122 万美元于 Insmed, Inc.，通过收购 8,472 股。其他机构投资者也增加了对这家生物制药公司的持股。分析师们为 Insmed 设定了不同的目标价格，普遍评级为 “买入”，平均目标价格为 203.45 美元。Insmed 的股票表现显示市值为 319.6 亿美元，市盈率为-24.21。最近有内部人士出售股票的报告，内部人士持有公司 3.00% 的股份</p>

<p>Wellington Shields Capital Management LLC acquired a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 8,472 shares of the biopharmaceutical company's stock, valued at approximately $1,220,000.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会（SEC）提交的文件，Wellington Shields Capital Management LLC 在第三季度收购了 Insmed, Inc.（NASDAQ:INSM - 免费报告）的新股份。该基金收购了 8,472 股这家生物制药公司的股票，价值约为 1,220,000 美元。</p>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素再平衡：3 只准备上涨的股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also bought and sold shares of the stock. Wellington Shields &amp; Co. LLC acquired a new stake in Insmed in the third quarter worth $569,000. Bessemer Group Inc. grew its stake in shares of Insmed by 137.5% in the 3rd quarter. Bessemer Group Inc. now owns 836 shares of the biopharmaceutical company's stock valued at $121,000 after buying an additional 484 shares during the period. SBI Securities Co. Ltd. increased its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 166 shares in the last quarter. Savant Capital LLC increased its position in Insmed by 36.7% in the 3rd quarter. Savant Capital LLC now owns 2,783 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 747 shares in the last quarter. Finally, Bridges Investment Management Inc. bought a new position in Insmed in the third quarter worth approximately $221,000.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也买卖了该股票的股份。Wellington Shields &amp; Co. LLC 在第三季度收购了价值 569,000 美元的 Insmed 新股份。Bessemer Group Inc.在第三季度将其在 Insmed 的股份增加了 137.5%。Bessemer Group Inc.现在拥有 836 股这家生物制药公司的股票，价值 121,000 美元，此前在此期间又购买了 484 股。SBI Securities Co. Ltd.在第三季度将其在 Insmed 的持仓增加了 404.9%。SBI Securities Co. Ltd.现在拥有 207 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。Savant Capital LLC 在第三季度将其在 Insmed 的持仓增加了 36.7%。Savant Capital LLC 现在拥有 2,783 股这家生物制药公司的股票，价值 401,000 美元，此前在上个季度又购买了 747 股。最后，Bridges Investment Management Inc.在第三季度购买了价值约 221,000 美元的 Insmed 新股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>INSM has been the subject of several recent research reports. Barclays started coverage on Insmed in a report on Tuesday, January 27th. They set an &#34;overweight&#34; rating and a $231.00 price objective for the company. HC Wainwright decreased their price target on shares of Insmed from $240.00 to $230.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, December 18th. UBS Group dropped their price objective on shares of Insmed from $223.00 to $215.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, January 6th. Wells Fargo &amp; Company set a $195.00 target price on shares of Insmed in a research report on Thursday, December 18th. Finally, Cantor Fitzgerald upped their target price on shares of Insmed from $216.00 to $230.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and an average target price of $203.45.</p>
<div class="lb-trans"><p>INSM 最近成为几份研究报告的主题。巴克莱在 1 月 27 日的报告中开始覆盖 Insmed。他们为该公司设定了 “增持” 评级和 231.00 美元的目标价。HC Wainwright 在 12 月 18 日的研究报告中将 Insmed 的目标价从 240.00 美元下调至 230.00 美元，并为该公司设定了 “买入” 评级。瑞银集团在 1 月 6 日的研究报告中将 Insmed 的目标价从 223.00 美元下调至 215.00 美元，并对该股票设定了 “买入” 评级。富国银行在 12 月 18 日的研究报告中为 Insmed 设定了 195.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 16 日的报告中将 Insmed 的目标价从 216.00 美元上调至 230.00 美元，并给予该股票 “增持” 评级。三位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 203.45 美元。</p>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on INSM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 INSM 的最新股票报告</strong></p>
</div><h2>Insmed Stock Performance</h2>
<div class="lb-trans"><h2>Insmed 股票表现</h2>
</div><p>NASDAQ INSM opened at $149.86 on Friday. The company has a fifty day moving average price of $174.90 and a 200-day moving average price of $159.93. The firm has a market cap of $31.96 billion, a price-to-earnings ratio of -24.21 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75.</p>
<div class="lb-trans"><p>NASDAQ INSM 在周五开盘价为 149.86 美元。该公司的 50 日移动平均价格为 174.90 美元，200 日移动平均价格为 159.93 美元。该公司的市值为 319.6 亿美元，市盈率为-24.21，贝塔值为 1.11。该公司的债务与股本比率为 0.59，流动比率为 4.63，速动比率为 4.34。Insmed, Inc.的 1 年最低价为 60.40 美元，1 年最高价为 212.75 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Michael Alexander Smith sold 640 shares of the firm's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the sale, the insider directly owned 56,397 shares of the company's stock, valued at $8,813,159.19. This trade represents a 1.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 274,857 shares of company stock valued at $50,121,247. Insiders own 3.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Michael Alexander Smith 在 2 月 3 日的交易中出售了 640 股该公司的股票。该股票以平均价格 156.27 美元出售，总交易额为 100,012.80 美元。出售完成后，该内部人士直接持有 56,397 股公司的股票，价值为 8,813,159.19 美元。这笔交易代表其持仓减少了 1.12%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站获取。此外，首席财务官 Sara Bonstein 在 2 月 3 日的交易中出售了 748 股 Insmed 股票。该股票以平均价格 156.34 美元出售，总价值为 116,942.32 美元。出售后，首席财务官在公司中持有 79,758 股，价值为 12,469,365.72 美元。这笔交易使其持股减少了 0.93%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了 274,857 股公司股票，价值为 50,121,247 美元。内部人士持有公司股票的 3.00%。</p>
</div><h2>Insmed Company Profile</h2>
<div class="lb-trans"><h2>Insmed 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，专注于靶向药物递送技术和新型制剂的研发，旨在改善治疗选择有限的患者的临床结果。</p>
</div><p>The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.</p>
<div class="lb-trans"><p>该公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Insmed 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 INSM 吗？</strong> 请访问 HoldingsChannel.com，获取 Insmed, Inc.（NASDAQ:INSM - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM

Market Beat

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

BNY Mellon Innovators ETF

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

DWA 医疗保健动量 ETF - Invesco

Insmed

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普全球医疗股指数 ETF - iShares

Wellington Shields Capital Management LLC 向 Insmed, Inc. $INSM 投资了 122 万美元